[go: up one dir, main page]

PE20070792A1 - Derivados lactama lactona como intermediarios en la sintesis de inhibidores de renina - Google Patents

Derivados lactama lactona como intermediarios en la sintesis de inhibidores de renina

Info

Publication number
PE20070792A1
PE20070792A1 PE2006001252A PE2006001252A PE20070792A1 PE 20070792 A1 PE20070792 A1 PE 20070792A1 PE 2006001252 A PE2006001252 A PE 2006001252A PE 2006001252 A PE2006001252 A PE 2006001252A PE 20070792 A1 PE20070792 A1 PE 20070792A1
Authority
PE
Peru
Prior art keywords
compounds
lactama
intermediaries
refers
synthesis
Prior art date
Application number
PE2006001252A
Other languages
English (en)
Inventor
Gottfried Sedelmeier
Dominique Grimler
Acemoglu Murat
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35451886&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20070792(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20070792A1 publication Critical patent/PE20070792A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
  • Indole Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS LACTAMA LACTONA DE FORMULA (II) Y (VI) DONDE R3 ES ALQUILO(C1-C7) O CICLOALQUILO(C3-C8); R4 ES ALQUILO(C1-C7), CICLOALQUILO, ENTRE OTROS; Act ES UN ACTIVADOR TAL COMO CARBAMATO; SIENDO PREFERIDO EL COMPUESTO 5-(5-OXO-TETRAHIDRO-FURA-2-NIL)PIRROLIDI-2-NONA. TAMBIEN SE REFIERE AUN PROCESO DE PREPARACION. DICHOS COMPUESTOS SON INTERMEDIARIOS EN LA PREPARACION DE COMPUESTOS INHIBIDORES DE RENINA TAL COMO ALISKIRAN ((2S,4S,5S,7S)-5-AMINO-N-(2-CARBANO-IL-2-METILPROPIL)-4-HIDROXI-2-ISOPROPIL-7[4-METOXI-3-(3-METOXIPROPOXI)BENCIL]-8-METILNONANAMIDA) PERMITIENDO OBTENER PRODUCTOS CON ALTA PUREZA Y DE MENOR COSTO. ADICIONALMENTE REFIERE LA TRANSFORMACION LOS COMPUESTOS (VI) CON COMPUESTOS METALO ORGANICOS (VII) DANDO ORIGEN A LOS COMPUESTOS (VIII) LOS CUALES SON COMPUESTOS PRECURSORES
PE2006001252A 2005-10-17 2006-10-16 Derivados lactama lactona como intermediarios en la sintesis de inhibidores de renina PE20070792A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0521083.6A GB0521083D0 (en) 2005-10-17 2005-10-17 Organic compounds

Publications (1)

Publication Number Publication Date
PE20070792A1 true PE20070792A1 (es) 2007-09-10

Family

ID=35451886

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2006001252A PE20070792A1 (es) 2005-10-17 2006-10-16 Derivados lactama lactona como intermediarios en la sintesis de inhibidores de renina
PE2011001455A PE20120581A1 (es) 2005-10-17 2006-10-16 Derivados lactama lactona como intermediarios en la sintesis de inhibidores de renina

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2011001455A PE20120581A1 (es) 2005-10-17 2006-10-16 Derivados lactama lactona como intermediarios en la sintesis de inhibidores de renina

Country Status (30)

Country Link
US (2) US7772405B2 (es)
EP (1) EP1948643B1 (es)
JP (3) JP5356031B2 (es)
KR (1) KR101294432B1 (es)
CN (2) CN101111493B (es)
AR (1) AR058089A1 (es)
AU (1) AU2006303489B2 (es)
BR (1) BRPI0617492A2 (es)
CA (2) CA2829487A1 (es)
CY (1) CY1114308T1 (es)
DK (1) DK1948643T3 (es)
EC (1) ECSP088368A (es)
ES (1) ES2427098T3 (es)
GB (1) GB0521083D0 (es)
HK (1) HK1120509A1 (es)
HR (1) HRP20130793T1 (es)
IL (1) IL190330A (es)
JO (1) JO2926B1 (es)
MY (1) MY145466A (es)
NO (1) NO342854B1 (es)
NZ (1) NZ567042A (es)
PE (2) PE20070792A1 (es)
PL (1) PL1948643T3 (es)
PT (1) PT1948643E (es)
RU (1) RU2432354C2 (es)
SI (1) SI1948643T1 (es)
TN (1) TNSN08170A1 (es)
TW (1) TWI395733B (es)
WO (1) WO2007045420A2 (es)
ZA (1) ZA200802632B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0521083D0 (en) * 2005-10-17 2005-11-23 Novartis Ag Organic compounds
DE102005052195A1 (de) * 2005-10-28 2007-05-03 Reuter Chemischer Apparatebau Kg Verfahren zur Herstellung von chiralen Octensäurederivaten
NZ579792A (en) * 2007-04-03 2012-03-30 Novartis Ag Processes for preparing lactone compounds
EP2173698A2 (en) * 2007-06-19 2010-04-14 Novartis Ag Process for the synthesis of intermediates of renin inhibitors such as aliskiren
DE102007049039A1 (de) * 2007-10-11 2009-04-16 Reuter Chemischer Apparatebau Kg Verfahren zur Herstellung von 8-Hydrazino-8-Aryl-Octanoylderivaten und deren Verwendung
SI2189442T1 (sl) * 2008-11-20 2015-03-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Postopek in intermediati za pripravo aliskirena
AU2010282623B2 (en) * 2009-08-11 2013-12-12 Massachusetts Institute Of Technology The ring opening of lactones and lactams
WO2011051853A1 (en) * 2009-10-29 2011-05-05 CarboDesign LLC Manufacturing process for preparing enaniomerically pure 8- aryloctanoic acid derivatives such as aliskiren
US20110137047A1 (en) * 2009-12-07 2011-06-09 CarboDesign LLC Process for enantiomerically pure 8-Aryloctanoic acids as Aliskiren
CN101774986B (zh) * 2010-01-06 2012-03-28 浙江天宇药业股份有限公司 一种制备阿利克伦及其中间体的方法
CN102241650B (zh) * 2010-05-14 2014-05-07 浙江九洲药业股份有限公司 用于制备阿立克仑的中间体化合物及相关制备方法
CN102485722B (zh) * 2010-12-06 2014-05-07 博瑞生物医药技术(苏州)有限公司 阿利克仑、其中间体和药用盐及制备方法
CN102775393B (zh) * 2011-05-09 2014-08-27 上海现代制药股份有限公司 一种药物中间体的制备方法
US8703976B2 (en) 2011-10-02 2014-04-22 Milan Soukup Manufacturing process for 8-aryloctanoic acids such as Aliskiren
CN102746182B (zh) * 2012-07-27 2014-09-03 浙江普洛医药科技有限公司 一种阿利克伦的制备方法
CN103059012B (zh) * 2013-01-30 2016-06-22 浙江海翔药业股份有限公司 1,8-二羰基-4,5-环氧化合物及其制备方法
CN104876832B (zh) * 2014-02-28 2016-12-07 华润双鹤药业股份有限公司 阿利吉仑的4-位差向异构体、其制备方法及用途
CN105294612A (zh) * 2014-06-05 2016-02-03 山东威智医药工业有限公司 阿利克仑中间体及其制备方法和应用
US10087190B1 (en) * 2017-04-24 2018-10-02 Purdue Research Foundation Lactones
CN114315749B (zh) * 2021-12-13 2024-04-26 湖南华腾医药有限公司 一种连续流微反应器合成阿利克仑中间体的方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY119161A (en) * 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
US5659065A (en) * 1994-04-18 1997-08-19 Novartis Corporation Alpha-aminoalkanoic acids and reduction products
US5606078A (en) * 1994-04-18 1997-02-25 Ciba-Geigy Corporation 3,5-Disubstituted tetrahydrofuran-2-ones
ES2312346T3 (es) 1999-07-29 2009-03-01 Speedel Pharma Ag Produccion de 2,7-dialquil-4-hidroxi-5-amino-8-aril-octanoilamidas n-sustituidas.
FR2801051B1 (fr) * 1999-11-17 2001-12-14 Adir Nouveaux composes aminopyrroline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6310904B1 (en) 2000-05-31 2001-10-30 Honeywell International, Inc. Measurement method to facilitate production of self-aligning laser gyroscope block
DK1215201T3 (da) 2000-12-14 2007-01-29 Speedel Pharma Ag Fremgangsmåde til fremstilling af aryloctanylamider
CN1258528C (zh) * 2001-09-07 2006-06-07 巴斯福股份公司 2－吡咯烷酮的制备方法
GB0212410D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Organic compounds
CN1882528A (zh) 2003-11-26 2006-12-20 诺瓦提斯公司 有机化合物
SV2005001973A (es) * 2003-12-12 2005-11-04 Wyeth Corp Quinolinas utiles en el tratamiento de enfermedades cardiovasculares ref. wyth0090-504 (am101500)
EP1699762A1 (en) * 2004-03-19 2006-09-13 Speedel Experimenta AG 5-amino-4-hydroxy-7-(1h-indolmethyl)-8-methylnonamide derivatives as renin inhibitors for the treatment of hypertension
EP1582523A1 (en) * 2004-04-02 2005-10-05 Ludwig-Maximilians-Universität München Method of preparing organomagnesium compounds
GB0419361D0 (en) * 2004-08-31 2004-10-06 Novartis Ag Organic compounds
GB0511686D0 (en) 2005-06-08 2005-07-13 Novartis Ag Organic compounds
GB0521083D0 (en) * 2005-10-17 2005-11-23 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
ECSP088368A (es) 2008-05-30
IL190330A0 (en) 2009-09-22
RU2008119276A (ru) 2009-11-27
DK1948643T3 (da) 2013-09-08
WO2007045420A3 (en) 2007-06-07
JP5792139B2 (ja) 2015-10-07
PT1948643E (pt) 2013-09-05
CN103121995A (zh) 2013-05-29
JO2926B1 (en) 2015-09-15
US8198465B2 (en) 2012-06-12
KR20080057285A (ko) 2008-06-24
CN103121995B (zh) 2016-08-03
KR101294432B1 (ko) 2013-08-07
SI1948643T1 (sl) 2013-10-30
ES2427098T3 (es) 2013-10-28
US20100267965A1 (en) 2010-10-21
US7772405B2 (en) 2010-08-10
HK1120509A1 (en) 2009-04-03
BRPI0617492A2 (pt) 2011-07-26
IL190330A (en) 2013-12-31
JP2014196312A (ja) 2014-10-16
ZA200802632B (en) 2009-04-29
CY1114308T1 (el) 2016-08-31
EP1948643A2 (en) 2008-07-30
WO2007045420A2 (en) 2007-04-26
CA2625034C (en) 2014-08-19
CN101111493A (zh) 2008-01-23
US20080262246A1 (en) 2008-10-23
TNSN08170A1 (en) 2009-10-30
MY145466A (en) 2012-02-15
CN101111493B (zh) 2013-02-13
CA2829487A1 (en) 2007-04-26
NO342854B1 (no) 2018-08-20
AU2006303489A1 (en) 2007-04-26
AR058089A1 (es) 2008-01-23
EP1948643B1 (en) 2013-06-05
TWI395733B (zh) 2013-05-11
RU2432354C2 (ru) 2011-10-27
NO20082263L (no) 2008-07-07
TW200800965A (en) 2008-01-01
AU2006303489B2 (en) 2011-04-07
PE20120581A1 (es) 2012-06-08
JP5356031B2 (ja) 2013-12-04
PL1948643T3 (pl) 2013-11-29
GB0521083D0 (en) 2005-11-23
JP2009514808A (ja) 2009-04-09
NZ567042A (en) 2012-02-24
CA2625034A1 (en) 2007-04-26
HRP20130793T1 (hr) 2013-09-30
JP2013032369A (ja) 2013-02-14

Similar Documents

Publication Publication Date Title
PE20070792A1 (es) Derivados lactama lactona como intermediarios en la sintesis de inhibidores de renina
ES2524045T3 (es) Nuevas amidas y tioamidas heteroaromáticas como plaguicidas
ES2587738T3 (es) Derivados de quinoxalina y quinolina como inhibidores de quinasa
NZ600110A (en) Process for the preparation of compounds useful as inhibitors of sglt
Zarei et al. 3-Thiolated 2-azetidinones: synthesis and in vitro antibacterial and antifungal activities
UA101482C2 (ru) Способ получения 2'-дезокси-5-азацитидина (децитабина)
CA2738706C (en) Synthesis of boronic ester and acid compounds
MX337714B (es) Derivado de imidazol de heteroanillo fusionado que tiene efecto de activacion de proteina cinasa activada por monofosfato de adenosina (amk).
EA201270550A1 (ru) Процесс получения соединений для применения в качестве ингибиторов sglt2
CO6160263A2 (es) Derivados de n-cicloalquil-bencil-tiocarboxamida o n-cicloalquil-bencil-amida n`-sustituida fungicidas
EA201070872A1 (ru) Производные азабициклических карбоксамидов, их получение и их применение в терапии
NO20072198L (no) Korrosjons- og gasshydratinhibitorer med foroket biologisk nedbrytbarhet og redusert toksisitet
MX2009003739A (es) Derivados de hidrobenzamida como inhibidores de hsp90.
AR060331A1 (es) Un proceso convergente para la sintesis de derivados de taxano
TW200630363A (en) Process for preparing trisubstituted pyrimidine compounds
SG170794A1 (en) Process for preparation of hiv protease inhibitors
ATE501103T1 (de) Organische verbindungen
NZ707276A (en) Compounds useful in the synthesis of benzamide compounds
AR079294A1 (es) Acidos homoglutamico y acidos glutamico marcados con yodo y metodo de preparacion de los mismos
GB2470170A (en) Dithienothiophene derivatives
TW200730480A (en) Organic compounds
AR037387A1 (es) Proceso para la preparacion de amidas de acido alfa-hidroxicarboxilico
NO970766D0 (no) Fremgangsmåte for fremstilling av taxol og derivater derav
IN2012DN02871A (es)
TW200619201A (en) Process for the preparation of pyrazoles

Legal Events

Date Code Title Description
FG Grant, registration